Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonia Cohen

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Cancer Medicine|December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic MutationsDerek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Neuron|October 11, 2011
Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and functionSonia Cohen, Harrison W Gabel, Martin Hemberg, et al.
Journal of the American Academy of Dermatology|March 21, 2023
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort studyBonnie W Leung, Guihong Wan, Nga Nguyen, et al.
Annals of Surgical Oncology|June 5, 2026
ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Neuron|October 19, 2006
Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturationZhaolan Zhou, Elizabeth J Hong, Sonia Cohen, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Overcoming impaired antigen presentation in tumor draining lymph nodes facilitates immunotherapyMeghan J O'Melia, Lutz Menzel, Pin-Ji Lei, et al.
Annals of Surgical Oncology|May 23, 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Nature Neuroscience|November 29, 2011
Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responsesDarren Goffin, Megan Allen, Le Zhang, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapyMeghan J O'Melia, Lutz Menzel, Pin-Ji Lei, et al.
Science Advances|November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcomeAlvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Cancer Medicine|December 4, 2025
Real-World Outcomes of Adjuvant Therapy in Stage III Melanoma and the Impact of Somatic MutationsDerek Effiom, Tyler Aprati, Anastasios Karneris, et al.
Neuron|October 11, 2011
Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous system development and functionSonia Cohen, Harrison W Gabel, Martin Hemberg, et al.
Journal of the American Academy of Dermatology|March 21, 2023
Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort studyBonnie W Leung, Guihong Wan, Nga Nguyen, et al.
Annals of Surgical Oncology|June 5, 2026
ASO Visual Abstract: Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Neuron|October 19, 2006
Brain-specific phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, dendritic growth, and spine maturationZhaolan Zhou, Elizabeth J Hong, Sonia Cohen, et al.
Biorxiv : the Preprint Server for Biology|September 26, 2025
Overcoming impaired antigen presentation in tumor draining lymph nodes facilitates immunotherapyMeghan J O'Melia, Lutz Menzel, Pin-Ji Lei, et al.
Annals of Surgical Oncology|May 23, 2026
Personalization of Neoadjuvant Immunotherapy in High-Risk Resectable Melanoma and Utility of ctDNA as a Biomarker of Immunotherapy ResponseAleigha Lawless, Derek N Effiom, Alma Burbano, et al.
Nature Neuroscience|November 29, 2011
Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responsesDarren Goffin, Megan Allen, Le Zhang, et al.
Journal for Immunotherapy of Cancer|December 30, 2025
Overcoming impaired antigen presentation in tumor-draining lymph nodes facilitates immunotherapyMeghan J O'Melia, Lutz Menzel, Pin-Ji Lei, et al.
Science Advances|November 14, 2020
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcomeAlvin Shi, Gyulnara G Kasumova, William A Michaud, et al.
Pageof 6